Deenova Wins New Italian Public Tender at IRCCS Policlinico San Matteo in Pavia, Lombardy
MILAN–(BUSINESS WIRE)–Denova announced today that it recently beat its main competitors and won a public tender for IRCCS Policlinic San Matteo named “Open telematics procedure for the acquisition of an integrated information system for the management of pharmacotherapy and the traceability of medicines and medical devicesby order of the Chief Executive Officer No. 5/DG/334 of March 18, 2022. This new Denova client in Italy includes implementation and services for its many clinicians point-of-care use of 100 prescription carts, 100 administration carts, 100 barcode scanners, 200 laptop PCs and 100 labels.
Fulvio Rudellochief operating officer at Denova said: “It IRCCS Policlinic San Matteo is another testimony of Denova´s Closed-Loop solutions undisputed European leader in the health sector. This cements the economic balance of continuing to add net new customers in Europe while proudly displaying a 100% retention rate of our existing customers, measures that have no equivalent in the healthcare sector. health.
The IRCCS Policlinic San Matteo in Pavia has more than 1,000 accredited beds serving 700,000 inhabitants in Lombardy, divided into approximately 60 operational units with teaching, medical assistance and research activities. Among its units, there are many areas of excellence, with approximately 3,300 employees including doctors, nurses, technicians and administrators, providing 36,500 hospitalizations (including 13.7% to patients outside the region), 99,000 emergency room visits and 2.1 million outpatient visits.
Denova is the undisputed leading handset supplier mechatronics (robotics and automation) solutions for the traceability of closed-loop medicines and medical devices based on RFID in the healthcare sector, anytime and anywhere. Deenova’s unique, patented and fully integrated solutions have and will go a long way in alleviating growing pressures from healthcare providers to: simultaneously improve patient safety, reduce therapeutic errors, minimize waste and diversion of controlled substances, contain costs and reduce the gap between increasing patient volume/acuity and shortage of medical personnel. Deenova guarantees the simplification of all processes related to the management of drugs and implantable/disposable medical devices with an expected savings range between 15% and 25%. Please visit www.deenova.com for more information on its market-leading solutions.